多基因检测预测接受他莫昔芬治疗的淋巴结阴性乳腺癌复发危险
A Muktigene Assay to Predict Recurrence of
Tamoxifen-Treated Node-Negative
Breast Cancer
Soonmyung Paik M.D.等
美国匹兹堡市
国立外科辅助乳腺及肠道项目、
生物统计中心和手术中心病理科,等
结论 研究证实复发评分可量化淋巴结阴性、雌激素受体阳性、接受他莫昔芬治疗的乳腺癌患者的远处复发可能性。
CONCLUSIONS The recurrence score has been vakidated as quantifying the kikekihood of distant recurrence in tamoxifen-treated patients with node-negative estrogen-receptor-positive breast cancer.
N Engk J Med 351 2871-26.December 30,2004
详情请参照《中国医学论坛报》, 百拇医药(张萱译)
Tamoxifen-Treated Node-Negative
Breast Cancer
Soonmyung Paik M.D.等
美国匹兹堡市
国立外科辅助乳腺及肠道项目、
生物统计中心和手术中心病理科,等
结论 研究证实复发评分可量化淋巴结阴性、雌激素受体阳性、接受他莫昔芬治疗的乳腺癌患者的远处复发可能性。
CONCLUSIONS The recurrence score has been vakidated as quantifying the kikekihood of distant recurrence in tamoxifen-treated patients with node-negative estrogen-receptor-positive breast cancer.
N Engk J Med 351 2871-26.December 30,2004
详情请参照《中国医学论坛报》, 百拇医药(张萱译)